Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer

  • Adam-Artigues, Anna
  • Garrido-Cano, Iris
  • Carbonell-Asins, Juan Antonio
  • Lameirinhas, Ana
  • Simón, Soraya
  • Ortega-Morillo, Belén
  • Martínez, María Teresa
  • Hernando, Cristina
  • Constâncio, Vera
  • Burgues, Octavio
  • Bermejo, Begoña
  • Henrique, Rui
  • Lluch, Ana
  • Jerónimo, Carmen
  • Eroles, Pilar
  • Cejalvo, Juan Miguel
[EN] The early diagnosis of breast cancer is essential to improve patients' survival rate. In this context, microRNAs have been described as potential diagnostic biomarkers for breast cancer. Particularly, circulating microRNAs have a strong value as non-invasive biomarkers. Herein, we assessed the potential of a microRNA signature based on miR-30b-5p and miR-99a-5p levels in plasma as a diagnostic biomarker for breast cancer. This two-microRNA signature was constructed by Principal Component Analysis and its prognostic value was assessed in a discovery cohort and blindly validated in a second cohort from an independent institution. ROC curve analysis and biomarker performance parameter evaluation demonstrated that our proposed signature presents a high value as a non-invasive biomarker for very early detection of breast cancer. In addition, pathway enrichment analysis identified three of the well-known pathways involved in cancer as targets of the two microRNAs., This study was financed by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) and FEDER funds (PI18/01219 to P.E. and CB16/12/00481 to A.Ll.) and from the Research Centre of the Portuguese Oncology Institute of Porto (PI 74-CBEG-CI-IPOP-19-2015 to C.J.). A.A.-A. and A.L. were funded by Asociación Española Contra el Cáncer (PRDVA18013LLUC and PRDVA19016LAME). V.C. was funded by Liga Portuguesa Contra o Cancro/Fundação PT. J.M.C. was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM). The authors are grateful to INCLIVA Biobank (PT17/0015/0049; B.000768 ISCIII) and Valencian Biobanking Network integrated into the Spanish National Biobanks Network and nursing staff from all institutions for collaboration.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Role of SALL4 in HER2+Breast Cancer Progression: Regulating PI3K/AKT Pathway

  • Pattanayak, Birlipta
  • Trigo-Lameirinhas, Ana Catarina
  • Torres-Ruiz, Sandra
  • Burgués, Octavio
  • AURA ROVIRA, ANA MARÍA
  • Martínez, Maite
  • Tapia, Marta
  • Zazo, Sandra
  • Albanell, Joan
  • Rojo, Federico
  • Bermejo, Begoña
  • Eroles-Asensio, Pilar
[EN] Treatment for the HER2+ breast cancer subtype is still unsatisfactory, despite breakthroughs in research. The discovery of various new molecular mechanisms of transcription factors may help to make treatment regimens more effective. The transcription factor SALL4 has been related to aggressiveness and resistance therapy in cancer. Its molecular mechanisms and involvement in various signaling pathways are unknown in the HER2+ breast cancer subtype. In this study, we have evaluated the implication of SALL4 in the HER2+ subtype through its expression in patients' samples and gain and loss of function in HER2+ cell lines. We found higher SALL4 expression in breast cancer tissues compared to healthy tissue. Interestingly, high SALL4 expression was associated with disease relapse and poor patient survival. In HER2+ cell lines, transient overexpression of SALL4 modulates PI3K/AKT signaling through regulating PTEN expression and BCL2, which increases cell survival and proliferation while reducing the efficacy of trastuzumab. SALL4 has also been observed to regulate the epithelial-mesenchymal transition and stemness features. SALL4 overexpression significantly reduced the epithelial markers E-cadherin, while it increased the mesenchymal markers beta-catenin, vimentin and fibronectin. Furthermore, it has been also observed an increased expression of MYC, an essential transcription factor for regulating epithelial-mesenchymal transition and/or cancer stem cells. Our study demonstrates, for the first time, the importance of SALL4 in the HER2+ subtype and partial regulation of trastuzumab sensitivity. It provides a viable molecular mechanism-driven therapeutic strategy for an important subset of HER2-overexpressing patients whose malignancies are mediated by SALL4 expression., We thank the patients who have agreed to participate in this study. We want to particularly acknowledge the INCLIVA BioBank (PT17/0015/0049; B.000768 ISCIII//) integrated in the Valencian Biobanking Network and the Spanish National Biobanks Network for its collaboration. We also express our gratitude to associations, individuals, and entities that collaborate with our research in breast cancer.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC

  • Pulido, I.
  • Garcia-Canaveras, J. C.
  • Rodriguez, M. L.
  • Becker, J. H.
  • Lopez, A.
  • Aupi, M.
  • Aparisi, S.
  • Chulia-Peris, L.
  • Tamayo-Torres, E.
  • Carreres-Rey, C.
  • Alcacer Fernandez-Coronado, J.
  • Benet, M.
  • Montero, S.
  • Mena, S.
  • Sandoval, J.
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Lung cancer is the deadliest neoplasia worldwide. Despite the availability of targeted therapies like tyrosine kinase inhibitors (TKIs) for EGFR-driven tumours in Non-Small Cell Lung Cancer (NSCLC), drug resistance remains a major factor that dramatically cuts life expectancy. Here we identify how increased expression of nicotinamide N-methyltransferase (NNMT) in TKI-resistant cancer cells diverts nicotinamide to synthesise 1-Methylnicotinamide (1-MNA) and lowers NAD+ levels that generates a druggable nicotinamide phosphoribosyltransferase (NAMPT) metabolic vulnerability. We also report that high blood levels of 1-MNA, the byproduct of NNMT activity, are significantly associated with lower survival rates in EGFR TKI-treated NSCLC patients. Taken together, our findings describe a new and highly specific non-genetic metabolic synthetic lethality for mesenchymal-like tumours, which exposes NAMPT as an in vivo druggable target and establishes 1-MNA as a novel liquid biopsy biomarker to predict and monitor EGFR TKI resistance in NSCLC., This work is supported by the Spanish Ministry of Science, Innovation and Universities (SAF2017-85352 and PID2020-119426RB-I00) and the Domingo Martinez Foundation to J. Carretero; NIH grant CA230778 and DoD CDMRP LCRP HT9425-23-1-0486, HT9425-23-1-0713, and HT9425-23-1-0497 to T. Shimamura; the European Regional Development Fund, the Carlos III Institute of Health of the Spanish Ministry of Science, Innovation and Universities (PI23/01369 and PI20/00580) to A. Lahoz; DoD CDMRP LCRP W81XWH-22-1-0023 to I. Pulido; and the Mansueto Lung Research Fund to Malek Massad. Part of the equipment used in this work was cofunded by the Generalitat Valenciana and the European Regional Development Fund (FEDER of the Comunitat Valenciana 2014-2020) . We gratefully acknowledge the support of the INCLIVA BioBank (PT17/0015/0049; B.000768 ISCIII) as part of the Valencian Biobanking Network and the Spanish National Biobanks Network. We thank Dr. Enrico Benedetti, Dr. Ajay Rana, and the Department of Surgery at the University of Illinois, Chicago, and Dr. Roque Bort from the La Fe Hospital for their help and support.